1. Home
  2. OABI vs ACHV Comparison

OABI vs ACHV Comparison

Compare OABI & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OmniAb Inc.

OABI

OmniAb Inc.

N/A

Current Price

$1.89

Market Cap

253.4M

Sector

Health Care

ML Signal

N/A

Logo Achieve Life Sciences Inc.

ACHV

Achieve Life Sciences Inc.

N/A

Current Price

$4.22

Market Cap

233.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OABI
ACHV
Founded
2012
N/A
Country
United States
United States
Employees
114
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
253.4M
233.7M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
OABI
ACHV
Price
$1.89
$4.22
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
$6.67
$15.50
AVG Volume (30 Days)
284.4K
337.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
17.33
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$74.84
N/A
Revenue Next Year
$40.54
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.22
$1.84
52 Week High
$3.33
$6.03

Technical Indicators

Market Signals
Indicator
OABI
ACHV
Relative Strength Index (RSI) 58.19 44.44
Support Level $1.85 $4.24
Resistance Level $2.15 $4.30
Average True Range (ATR) 0.10 0.23
MACD 0.03 0.01
Stochastic Oscillator 61.54 26.95

Price Performance

Historical Comparison
OABI
ACHV

About OABI OmniAb Inc.

OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.

About ACHV Achieve Life Sciences Inc.

Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.

Share on Social Networks: